Atlas Trials

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Clinical trial NCT05385861 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT05385861
Sponsor
National Health Research Institutes, Taiwan
Status
ENROLLING_BY_INVITATION
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
GEP-NET
Start date
2025-08-14
Primary completion
2025-12-31
Enrollment
52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.